Piper Sandler reiterated its Overweight rating on Amgen (NASDAQ:AMGN) shares, maintaining a price target of $310.00. The company, which boasts a "GOOD" overall financial health score according to ...

The CodeBreaK 300 results demonstrated that Lumakras 960 mg daily plus Vectibix (n=53) showed an improved median ...

Amgen Inc (AMGN) stock saw a modest uptick, ending the day at $268.94 which represents a slight increase of $1.84 or 0.69% from the prior close of $267.1. The stock opened at $269.33 and touched a low ...

Amgen's stock price remains nearly unchanged over 1.5 years, but its valuation may now be more reasonable or even a bargain.

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $310.00. The ...

Amgen (NASDAQ:AMGN – Get Free Report) had its target price reduced by investment analysts at Truist Financial from $333.00 to ...

Amgen Inc. closed $79.75 short of its 52-week high ($346.85), which the company achieved on July 25th.

The latest trading session saw Amgen (AMGN) ending at $267.10 ... in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank ...

Amgen Inc (AMGN) stock saw a decline, ending the day at $262.23 which represents a decrease of $-1.98 or -0.75% from the prior close of $264.21. The stock opened at $260.79 and touched a low of ...

Article analyzes Amgen's strong clinical progress and financials, recommending caution due to valuation and technical ...

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Amgen (AMGN – Research Report), retaining the price target of $362.00.Stay ...